Venus Remedies Limited has completed its mandatory quarterly compliance filing under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted its compliance certificate as required under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing Details

The compliance filing was submitted on April 8, 2026, by Company Secretary Neha on behalf of Venus Remedies Limited. The submission included a confirmation certificate received from the company's registrar and transfer agent, MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited.

Confirmation Certificate from Registrar

MUFG Intime India Private Limited issued the confirmation certificate on April 6, 2026, addressing the mandatory requirements under SEBI regulations. The certificate was signed by Swapan Kr Naskar, Associate Vice-President & Head (Delhi Branch) of MUFG Intime India Private Limited.

The registrar confirmed several key compliance aspects:

• Securities received from depository participants for dematerialization during Q4 FY26 were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where previously issued securities are listed
• Security certificates received for dematerialisation were confirmed or rejected as appropriate
• Security certificates were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners within prescribed timelines

Company Information

Venus Remedies Limited operates from multiple locations with its registered office at SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra, Chandigarh 160101. The company maintains its corporate office at 51-52, Industrial Area, Phase-I, Panchkula, Haryana 134113.

The pharmaceutical company operates manufacturing units across India and internationally, including facilities in Panchkula, Baddi, and a unit in Werne, Germany through Venus Pharma GmbH. This quarterly compliance filing demonstrates the company's adherence to regulatory requirements and proper maintenance of shareholder records through its appointed registrar and transfer agent.

Venus Remedies Limited has filed its yearly disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 31(4) for the financial year ended March 31, 2026. The disclosure was submitted to both National Stock Exchange of India Ltd. and BSE Limited on April 4, 2026.

Key Disclosure Details

The disclosure was filed by Pawan Chaudhary, Managing Director of Venus Remedies Limited, on behalf of all promoters and promoter group members along with persons acting in concert. The filing confirms compliance with SEBI regulations regarding substantial acquisition of shares and takeover provisions.

Share Encumbrance Status

The company has declared that no equity shares of promoters and promoters' group are encumbered or pledged as of March 31, 2026. The disclosure specifically states that promoters and promoter group members have not made or released any encumbrance of shares, directly or indirectly, other than those already disclosed to the stock exchanges.

Promoter and Promoter Group Composition

The disclosure covers six entities within the promoter and promoter group structure:

Regulatory Compliance

The filing demonstrates Venus Remedies Limited's adherence to SEBI's transparency requirements under the Substantial Acquisition of Shares and Takeovers Regulations, 2011. The disclosure was digitally signed by Pawan Chaudhary on April 3, 2026, and subsequently forwarded to the stock exchanges by Company Secretary Neha on April 4, 2026.

The company maintains its corporate office at Industrial Area, Phase-I, Panchkula, Haryana, with its registered office located in Chandigarh. Venus Remedies Limited operates multiple manufacturing units across India and Germany, reflecting its diversified operational presence in the pharmaceutical sector.